Trends in Allogeneic Transplantation for Favorable Risk Acute Myeloid Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT

Autor:	Nagler, Arnon, Labopin, Myriam, Salmenniemi, Urpu, Wu, Depei, Blaise, Didier, Rambaldi, Alessandro, Remenyi, Peter, Forcade, Edouard, de Latour, Régis Peffault, Chevallier, Patrice, Borne, Peter von dem, Burns, David, Schmid, Christoph, Maertens, Johan, Kroger, Nicolaus, Bug, Gesine, Aljurf, Mahmoud, Vydra, Jan, Halaburda, Kazimierz, Ciceri, Fabio, Mohty, Mohamad
Zdroj:	Transplantation and Cellular Therapy; February 2024, Vol. 30 Issue: 2, Number 2 Supplement 1 pS337-S338, 2p
Abstrakt:	Allogeneic transplantation (HSCT) is usually not indicated in favorable risk AML at CR1due to transplant-related mortality. However, in recent years, HSCTs are with significantly lower mortality.
Databáze:	Supplemental Index
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect